Friday, May 20, 2016 3:24:15 AM
Toyama Chemical's AD drug {from their website)
T-817MA
"Currently available drugs for AD in the world are mainly choline esterase inhibitors, which provide symptomatic relief through activating acetylcholinergic neuron in the brain. According to this mechanism, however, such drugs are regarded to be ineffective at addressing the underlying causes of the disease, and do not prevent the progression of the disease in the long term."
I agree. And Anavex knows this as well. That is the "10 cups of coffee" scenerio.
"T-817MA has neuroprotective properties. Toyama Chemical has demonstrated that T-817MA prevents neurodegeneration induced by Amyloid-ß protein. Accumulation of Amyloid-ß protein is considered to be central to the pathogenesis of AD. The neuroprotective properties of T-817MA were also observed in a mutant tau induced AD model. Besides these neuroprotective properties, T-817MA also promotes neurite outgrowth. On the basis of the currently available nonclinical data, Toyama Chemical considers T-817MA to be one of the most promissing neuroprotective agents in preventing the progression of AD."
That is not how Anavex 2-73 works. Blowing away nasty amloid proteins has been proven to be a dead end when taken as an end in itself. The reason the cells are puking out protein tangles is because they are sick. The reason these nueral cells stop working properly to retrieve memory is because they are sick and although cleaning away the mess helps the signals get through, when the cells starts losing their ability to signal, it doesn't do any good because the cells are still sick.
This other thing they report that T-817MA does is very different from Anavex 2-73 if not a little alarming. The promotion of nuerite outgrowth makes it appear to act like a kind of growth hormone. Considering the abysmal results obtained in clinical trials with trying to inject stem cells into spinal injury victims, its value in treating AD seems dubious. Stroke victims, maybe, if the new sprouts could somehow find their way to connect to the right destinations cells bypassing the dead ones. What was bad about the stem cell treatments is that they left the patients still paralyzed but now paralyzed and in pain, as if the new cells cross onnected with some pain cells instead of the motor neurons as hoped. Hard to say what would happen in the brain if the wrong connections were bridged. Probably nothing too good. Otherwise, at best, maybe relearn some function, but that is not the same thing as restoring memory.
Wikipedia Note: "A neurite refers to any projection from the cell body of a neuron. This projection can be either an axon or a dendrite. The term is frequently used when speaking of immature or developing neurons, especially of cells in culture, because it can be difficult to tell axons from dendrites before differentiation is complete."
OK. Non-clinical experiments on cells floating in petri dishes. Not even ready for rats, apparently.
http://www.toyama-chemical.co.jp/en/rd/area/cns.html
Unlike what's out there now, Anavex 2-73 actually repairs what has gone wrong in the cells and makes them better again. It's like spark plug wires on your car engine. They start falling off, it's going to run like sh*t and start spewing black smoke, clogging up. Enough of them fall off and it stops working altogether. Perhaps a picture from the corporate presentation makes it easier to understand. You see how the molecules on the keft have become unzipped? Anavex 2-73 zips them back up again. That's why it works better than anything else being tried.
http://s32.postimg.org/kuy4xdnet/endoplasmic.jpg
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM